MedTrace Logo

VITROS Immunodiagnostic Products NT-proBNP II

NCT03548909 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 3246

Last updated 2020-03-09

No results posted yet for this study

Summary

Amino Terminal pro-Brain Natriuretic Peptide (NTproBNP) is secreted in conditions of cardiac wall stress. NTproBNP levels are used in addition to clinical assessment to diagnose heart failure (HF). The purpose of this clinical study is to collect data to substantiate the use of the VITROS NT-proBNP II assay.

Conditions

Interventions

DIAGNOSTIC_TEST

VITROS Immunodiagnostic Products

NT-proBNP II assay

Sponsors & Collaborators

  • Ortho-Clinical Diagnostics, Inc.

    lead INDUSTRY

Principal Investigators

  • Robert Christenson, PhD · University of Maryland, College Park

Eligibility

Min Age
22 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-06-06
Primary Completion
2019-10-17
Completion
2019-10-17
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03548909 on ClinicalTrials.gov